Introduction
RPR 106972 is a new oral streptogramin consisting of a mixture of 45% RPR 112808 (pristinamycin I group) and 55% RPR 106950 (pristinamycin II group). It is chemically related to the injectable streptogramin, RP 59500 (quinupristin-dalfopristin), which has been shown to have activity against Legionella spp. in vitro. 1, 2 The purpose of this study was to examine the in-vitro activity of the oral streptogramin, RPR 106972, against Legionella spp. Our first objective was to determine if RPR 106972 was as active as erythromycin against clinical isolates of Legionella spp. Additionally, we set out to determine if the oral streptogramin would demonstrate synergy with rifampicin or ciprofloxacin against these same clinical isolates.
Materials and methods

Bacterial strains
Organisms were obtained from the University of Illinois Hospital (Chicago, IL, USA), Northwestern University Hospital (Chicago, IL, USA), Abbott Laboratories (Chicago, IL, USA), the Center for Disease Control (CDC) (Atlanta, GA, USA), and the American Type Culture Collection (ATCC) (Rockville, MD, USA). The legionella organisms tested included 40 clinical isolates and five ATCC control strains (Legionella pneumophila 33152, Legionella bozemanii 33217, Legionella. dumoffii 33279, Legionella gormanii 33297 and Legionella longbeachae 33462). Seventy-six per cent (34/45) of the organisms were 
Susceptibility and synergy testing procedures
The agar dilution method was used to determine MICs and test for synergy. 3 The medium used was buffered charcoal yeast extract (BCYE) agar. The standard chequerboard technique was used to determine the activity of RPR 106972 when combined with rifampicin or ciprofloxacin. 4 A direct suspension of the organisms was prepared in sterile water to match the turbidity of a 0.5 McFarland standard using a spectrophotometer at 625 nm. This suspension was further diluted 1:100. A replicator device was used to inoculate approximately 8 L of each bacterial suspension to the BCYE agar plates, resulting in a final inoculum of approximately 10 4 cfu/spot. All tests were performed in duplicate, and all plates were incubated at 35°C in humidified room air for 48 h. The MIC was read as the lowest 4 The activity ranges used for interpretation of the FIC indices were as follows: 0.5, synergy; 0.5-1, additive; 1-4, indifference; 4, antagonism.
Results and discussion
In this study we compared the in-vitro activity of RPR 106972 with that of erythromycin against 45 Legionella spp. The MIC 50 , MIC 90 and MIC ranges are all listed in Table I . Our data indicate that the oral streptogramin has good invitro activity against Legionella spp. The MICs of RPR 106972 were similar to those of erythromycin and ciprofloxacin. In addition, preliminary data indicate that RPR 106972 is more rapidly bactericidal than erythromycin against L. pneumophila at concentrations that should be readily attainable within macrophages. 5 We also looked at the synergic potential of rifampicin and ciprofloxacin when added to the oral streptogramin and tested against the same organisms. Results of the chequerboard tests are listed in Table II. RPR 106972 showed no synergy with rifampicin or ciprofloxacin. Commonly indifference was seen with both combinations, although additive effects were observed in 30% (13/43) of rifampicin combinations and 11% (5/45) of ciprofloxacin combinations. Of the RPR 106972-rifampicin combinations, the non-pneumophila species demonstrated the greatest activity, with additive results obtained with 64% of the organisms. No antagonism was observed with any of the combinations.
We chose BCYE agar for MIC and chequerboard testing because of our previous experience with problems of inadequate growth with some strains of Legionella spp. and with difficulty in interpreting results due to poor growth on media not containing charcoal. 6 While the MICs of erythromycin, ciprofloxacin and rifampicin are higher on charcoal media, they are still within clinically achievable One explanation for the apparent lack of synergy between rifampicin or ciprofloxacin and RPR 106972 involves the mechanism of action of these agents. The absence of synergy between rifampicin and RPR 106972 may be due to competition for binding sites on bacterial ribosomes. For the streptogramin-fluoroquinolone combination, RPR 106972 may diminish the bactericidal activity of ciprofloxacin without suppressing its ability to inhibit DNA synthesis. Hooper et al. 7 demonstrated loss of bactericidal activity of fluoroquinolone antimicrobials when combined with protein or RNA synthesis inhibitors, even though inhibition of DNA synthesis was unaffected. This finding suggests that fluoroquinolones may possess another site of action in addition to the A subunit of DNA gyrase. 8 Another explanation for lack of synergy may be that the methods used in this study, i.e., chequerboard technique, and charcoal-containing media, may have influenced the reported findings. Additional studies (i.e., time-kill curves, intracellular susceptibilities) are needed to confirm these initial results.
In conclusion, we think that RPR 106972 warrants further investigation for the treatment of legionella infections. When combined with rifampicin or ciprofloxacin the activity of RPR 106972 should not be decreased and may indeed be enhanced against some strains of legionella.
